Cervical cancer prevention advances with new immunotherapy findings, addressing disparities and improving outcomes for ...

A phase 2 trial shows promising results for pembrolizumab combined with cisplatin and radiation in treating unresectable ...

The drug Trodelvy (drug name sacituzumab govitecan-hziy) is showing promise for first-line metastatic triple-negative breast ...

Pembrolizumab added to twice weekly gemcitabine plus transurethral muscle-invasive urothelial cancer resection of a bladder tumor and hypofractionated radiation therapy appeared safe for patients ...

would result in a benefit with respect to progression-free survival in patients with advanced stage or recurrent endometrial cancer. The median progression-free survival in the pembrolizumab arm ...

A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of disease progression or death in ovarian cancer patients without BRCA mutations ...

approved Keytruda ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) for the treatment of adult patients with locally advanced or metastatic urothelial cancer. Previously, the treatment ...

Merck’s blockbuster PD-1 inhibitor pembrolizumab (Keytruda) may be effective against endometrial cancer in some settings, but a statement today from the company shows that’s not so for all ...

He underlined that the results do indicate the "clinically significant EFS benefits" of pembrolizumab in this population "extend to patients with residual viable tumors," with the drug associated ...

Moderna says the same mRNA technology that fueled its COVID-19 vaccine is proving effective in fighting melanoma. The company presented the latest results from its trial involving 157 people with ...

The US Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for locally advanced unresectable or metastatic biliary tract cancer in combination with gemcitabine and cisplatin.

Standard first-line chemotherapy for endometrial cancer is paclitaxel plus carboplatin. The benefit of adding pembrolizumab to chemotherapy remains unclear. In this double-blind, placebo ...